Definium Therapeutics, Inc.

NASDAQ:DFTX

Biotechnology

Healthcare
$29.12 -1.67%

-$0.41 today

Market cap
$3.99B
Beta
2.38
P/E (TTM)
-11.0
EPS (TTM)
-$2.18
52W Low $12.88High $26.15

Volume 1.91M

Average 2.67M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$131.56M

FY 2025 · Annual

Investing Cash Flow

-$151.61M

FY 2025 · Annual

Financing Cash Flow

$267.27M

FY 2025 · Annual

+5.6% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(93.04M)(56.8M)(95.73M)(108.68M)(183.79M)
Depreciation & Amortization2.62M3.18M3.16M527K0
Deferred Income Tax(1.16M)0(2.03M)00
Stock-Based Compensation42.72M13.71M15.49M16.91M20.1M
Change in Working Capital1.88M(3.78M)6.28M(3.34M)9.44M
Accounts Receivables00000
Inventory00000
Accounts Payables1.28M(2.06M)2.03M(2.13M)3.34M
Other Working Capital598K(1.73M)4.26M(1.22M)6.1M
Other Non-Cash Items1.16M(6.45M)8.46M15.45M22.7M
Operating Cash Flow(45.82M)(50.14M)(64.37M)(79.13M)(131.56M)
Capital Expenditures00000
Acquisitions (Net)(297K)0000
Purchases of Investments0000(268.36M)
Sales of Investments0000116.75M
Other Investing Activities00000
Investing Cash Flow(297K)000(151.61M)
Debt Repayment0014.16M10.86M20M
Common Stock Issued81.92M42.3M7.53M250M259.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities16.9M16.75M163K(7.66M)(12.63M)
Financing Cash Flow98.82M59.05M21.85M253.2M267.27M
Effect of Forex Changes742K(309K)79K(30K)(7K)
Net Change in Cash53.45M8.6M(42.44M)174.04M(15.9M)
Free Cash Flow(45.82M)(50.14M)(64.37M)(79.13M)(131.56M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$183.8M
+ D&A$0
+ Stock-Based Comp$20.1M
+ Deferred Tax$0
+ Working Capital$9.4M
+ Other Non-Cash$22.7M
= Operating Cash Flow-$131.6M
- Capex$0
= Free Cash Flow-$131.6M

Analysis

FY2025 free cash flow is -$131.6M. FCF conversion is 71.6% of net income. Operating cash flow was -$131.6M, with capex of $0. The largest bridge item is Other Non-Cash at $22.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 13, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
SC 13GSC 13G filingNov 5, 2026
4Statement of changes in beneficial ownershipSep 29, 2026

Does DFTX generate free cash flow?

Definium Therapeutics, Inc. (DFTX) generated -$131.56M of free cash flow in fiscal 2025.

How much operating cash flow does DFTX produce?

Operating cash flow was -$131.56M, before capital expenditures of $0.00.